<DOC>
	<DOC>NCT00987272</DOC>
	<brief_summary>The purpose of the study is to demonstrate safety and efficacy of Olopatadine 0.2% compared to its vehicle in Japanese subjects in the treatment of acute allergen-mediated conjunctivitis using the conjunctival allergen challenge (CAC) test.</brief_summary>
	<brief_title>Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Japanese ethnicity. Seasonal Allergic Conjunctivitisasymptomatic. Other protocoldefined inclusion criteria may apply. Manifest signs and symptoms of clinically active allergic conjunctivitis in either eye (&gt;1 for redness in any of the 3 vessels beds conjunctival, episcleral, ciliary or itching &gt;0) at the start of any visit. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Allergies</keyword>
	<keyword>Ocular</keyword>
</DOC>